ArticleJournal of Cancer2021

Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC).

Xiaoting Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.